| ［1］ |
Simons FE, Simons KJ. Histamine and H1⁃antihistamines: celebrating a century of progress［J］. J Allergy Clin Immunol, 2011, 128（6）: 1139⁃1150.e4. DOI: 10.1016/j.jaci.2011.09.005.
|
| ［2］ |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA（2） LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update［J］. Allergy, 2014, 69（7）: 868⁃887. DOI: 10.1111/all.12313.
|
| ［3］ |
中华医学会皮肤性病学分会免疫学组. 中国荨麻疹诊疗指南（2014版）［J］. 中华皮肤科杂志, 2014, 47（7）: 514⁃516. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.07.019.
|
| ［4］ |
Sharma M, Bennett C, Carter B, et al. H1⁃antihistamines for chronic spontaneous urticaria: an abridged cochrane systematic review［J］. J Am Acad Dermatol, 2015, 73（4）: 710⁃716.e4. DOI: 10.1016/j.jaad.2015.06.048.
|
| ［5］ |
Takahashi H, Kaneko S, Chinuki Y, et al. Clinical efficacy of loratadine for chronic urticaria refractory to other antihistamines［J］. Nishi Nihon Hifuka, 2012, 74（3）: 293⁃300. DOI: 10.2336/nishinihonhifu.74.293.
|
| ［6］ |
Yamanaka K, Motomura E, Noro Y, et al. Olopatadine, a non⁃sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis［J］. Exp Dermatol, 2015, 24（3）: 227⁃229. DOI: 10.1111/exd.12630.
|
| ［7］ |
Hossen MA, Fujii Y, Ogawa M, et al. Effect of loratadine on mouse models of atopic dermatitis associated pruritus［J］. Int Immunopharmacol, 2005, 5（7⁃8）: 1331⁃1336. DOI: 10.1016/j.intimp.2005.02.004.
|
| ［8］ |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2014版）［J］.中华皮肤科杂志, 2014, 47（7）: 511⁃514. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.07.018.
|
| ［9］ |
中华医学会皮肤性病学分会免疫学组. 湿疹诊疗指南（2011年）［J］.中华皮肤科杂志, 2011, 44（1）: 5⁃6. DOI: 10.3760/cma.j.issn.0412⁃4030.2011.01.002.
|
| ［10］ |
O′Donoghue M, Tharp MD. Antihistamines and their role as antipruritics［J］. Dermatol Ther, 2005, 18（4）: 333⁃340. DOI: 10.1111/j.1529⁃8019.2005.00034.x.
|
| ［11］ |
Paul E. Treatment of pruritic skin diseases with loratadine. Results of an open multicenter study［J］. Fortschr Med, 1991, 109（7）: 175⁃178.
|
| ［12］ |
Simons FE. Prospective, long⁃term safety evaluation of the H1⁃receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC study group. early treatment of the atopic child［J］. J Allergy Clin Immunol, 1999, 104（2 Pt 1）: 433⁃440.DOI: 10.1016/S0091⁃6749（99）70389⁃1.
|
| ［13］ |
Mann RD, Pearce GL, Dunn N, et al. Sedation with "non⁃sedating" antihistamines: four prescription⁃event monitoring studies in general practice［J］. BMJ, 2000, 320（7243）: 1184⁃1186. DOI: 10.1136/bmj.320.7243.1184.
|
| ［14］ |
Affrime MB, Brannan MD, Lorber RR, et al. A 3⁃month evaluation of electrocardiographic effects of loratadine in healthy individuals［J］. Adv Ther, 1999, 16（4）: 149⁃157.
|
| ［15］ |
Simons FE, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double⁃blind, placebo⁃controlled study［J］. J Allergy Clin Immunol, 2003, 111（6）: 1244⁃1248. DOI: 10.1067/mai.2003.1496.
|
| ［16］ |
Grimfeld A, Holgate ST, Canonica GW, et al. Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study［J］. Clin Exp Allergy, 2004, 34（11）: 1665⁃1672. DOI: 10.1111/j.1365⁃2222.2004.02098.x.
|
